This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Lymphogranuloma venerum

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lymphogranuloma venerum is a tropical sexually transmitted disease caused by Chlamydia trachomatis (L1,L2,L3).

It is endemic in Africa, India, SE Asia, South America and the Caribbean, with men affected more commonly than women, principally between the age 20 to 30 years.

There are three stages to the disease:

  • an asymptomatic ulcer which resolves rapidly
  • an inguinal syndrome, between 1 week and 6 months later, with adenopathy (lymph nodes are painful) and bubo development. There is often systemic illness and malaise
  • regional abscess or fistula, resulting in regional strictures, e.g. rectal strictures

Diagnosis is by serology and intradermal skin test with LGV antigen - Frei's test.

The condition spontaneously remits, but can be treated with tetracyclines or erythromycin. Patients with LGV may also harbour other sexually transmitted disease including syphilis.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.